C-Rad AB (publ) (CRAD-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.10 Million ≈ $7.65 Million USD) by net assets (Skr347.20 Million ≈ $37.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of C-Rad AB (publ) to measure how much of total assets are equity-financed.
C-Rad AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how C-Rad AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check C-Rad AB (publ) cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
C-Rad AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C-Rad AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Li-FT Power Ltd.
F:WS0
|
-0.002x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.032x |
|
LIWANLI Innovation Co Ltd
TW:3054
|
-0.056x |
|
OM Holdings Ltd
KLSE:5298
|
-0.004x |
|
Merit Turizm Yatirim ve Isletme AS
IS:MERIT
|
0.006x |
|
Humanica Public Company Limited
BK:HUMAN
|
0.044x |
|
Jeld-Wen Holding Inc
NYSE:JELD
|
0.098x |
|
Hunter Group ASA
OL:HUNT
|
-0.134x |
Annual Cash Flow Conversion Efficiency for C-Rad AB (publ) (2008–2025)
The table below shows the annual cash flow conversion efficiency of C-Rad AB (publ) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see CRAD-B stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr347.20 Million ≈ $37.36 Million |
Skr71.10 Million ≈ $7.65 Million |
0.205x | +121.28% |
| 2024-12-31 | Skr324.99 Million ≈ $34.97 Million |
Skr30.08 Million ≈ $3.24 Million |
0.093x | -21.94% |
| 2023-12-31 | Skr281.60 Million ≈ $30.30 Million |
Skr33.38 Million ≈ $3.59 Million |
0.119x | +196.73% |
| 2022-12-31 | Skr242.54 Million ≈ $26.10 Million |
Skr9.69 Million ≈ $1.04 Million |
0.040x | -49.18% |
| 2021-12-31 | Skr231.09 Million ≈ $24.87 Million |
Skr18.17 Million ≈ $1.96 Million |
0.079x | -14.85% |
| 2020-12-31 | Skr199.79 Million ≈ $21.50 Million |
Skr18.45 Million ≈ $1.99 Million |
0.092x | -51.38% |
| 2019-12-31 | Skr83.33 Million ≈ $8.97 Million |
Skr15.83 Million ≈ $1.70 Million |
0.190x | +285.14% |
| 2018-12-31 | Skr93.64 Million ≈ $10.08 Million |
Skr-9.61 Million ≈ $-1.03 Million |
-0.103x | -82.21% |
| 2017-12-31 | Skr71.41 Million ≈ $7.68 Million |
Skr-4.02 Million ≈ $-432.62K |
-0.056x | +91.09% |
| 2016-12-31 | Skr70.60 Million ≈ $7.60 Million |
Skr-44.62 Million ≈ $-4.80 Million |
-0.632x | -10.29% |
| 2015-12-31 | Skr40.05 Million ≈ $4.31 Million |
Skr-22.95 Million ≈ $-2.47 Million |
-0.573x | -38.13% |
| 2014-12-31 | Skr40.04 Million ≈ $4.31 Million |
Skr-16.61 Million ≈ $-1.79 Million |
-0.415x | +30.97% |
| 2013-12-31 | Skr38.03 Million ≈ $4.09 Million |
Skr-22.86 Million ≈ $-2.46 Million |
-0.601x | +25.17% |
| 2012-12-31 | Skr16.26 Million ≈ $1.75 Million |
Skr-13.06 Million ≈ $-1.41 Million |
-0.803x | -41.62% |
| 2011-12-31 | Skr36.02 Million ≈ $3.88 Million |
Skr-20.43 Million ≈ $-2.20 Million |
-0.567x | -444.26% |
| 2010-12-31 | Skr48.12 Million ≈ $5.18 Million |
Skr-5.01 Million ≈ $-539.60K |
-0.104x | +64.39% |
| 2009-12-31 | Skr29.82 Million ≈ $3.21 Million |
Skr-8.73 Million ≈ $-939.06K |
-0.293x | -2.01% |
| 2008-12-31 | Skr35.05 Million ≈ $3.77 Million |
Skr-10.06 Million ≈ $-1.08 Million |
-0.287x | -- |
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more